Dol-P-Man:Man(5)GlcNAc(2)-PP-Dol alpha-1,3-mannosyltransferase (ALG3) adds the sixth mannose (although the first to be derived from dolichyl-phosphate-mannose, DOLPman) to the lipid-linked oligosaccharide intermediate GlcNAc(2) Man(5) (PPDol)1 (Korner et al. 1999). Defects in ALG3 are associated with congenital disorder of glycosylation 1d (ALG3-CDG, CDG1d; MIM:601110), a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterised by under-glycosylated serum glycoproteins. CDG type 1 diseases result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. (Sun et al. 2005). Point mutations that cause ALG3-CDG are G118D, R171Q, W71R and M157K (Korner et al. 1999, Sun et al. 2005, Kranz et al. 2007).
Körner, C, Lehle, L, von Figura, K, Marquardt, T, Stephani, U, Knauer, R
Krasnewich, D, Freeze, HH, Sun, L, Casey, JR, Eklund, EA, Kranz, C
Cohen, J, Chung, WK, Freeze, HH, Wang, C, Eklund, EA, Sun, L
alpha-1,3-mannosyltransferase activity of ALG3 mutants [endoplasmic reticulum membrane]
Loss of function of ALG3 mutants [endoplasmic reticulum membrane]
© 2022 Reactome
